CRSP - Is Portola Pharmaceuticals a Buy?
Portola Pharmaceuticals (NASDAQ: PTLA) might be relatively unheard of compared to its more popular peers. However, the $2.1 billion biotech stock has some promising drug candidates in the pipeline, with at least one poised to become a major blockbuster. Over the past couple of years, Portola launched two major drug therapies that were highly anticipated by investors and analysts alike. The first, Bevyxxa, ended up being a disappointment, while the second, Andexxa, has had a bit of a slow start in 2019 from a production standpoint.
However, with Portola Pharmaceuticals reporting strong financial results in its recent quarterly statement, the case for this biotech stock might be stronger now than it has been in years.
IMAGE SOURCE: GETTY IMAGES.